ArticleOncology letters2026
Pre-radiotherapy modified prognostic nutritional index predicts acute radiation enteritis in patients with cervical cancer undergoing radiotherapy: A retrospective study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute radiation enteritis (ARE) is a common complication of pelvic radiotherapy in patients with cervical cancer and may adversely affect treatment tolerance and nutritional status. The present retrospective study investigated whether the pre-radiotherapy modified prognostic nutritional index (mPNI), a cholesterol-modified nutritional and immune-related score, is associated with ARE in patients with cervical cancer receiving radiotherapy. A total of 92 patients with pathologically confirmed cervical cancer who completed radiotherapy at Fuyang People's Hospital Affiliated to Anhui Medical University (Fuyang, China) between January 2023 and December 2025 were included. ARE was graded according to the Radiation Therapy Oncology Group acute lower gastrointestinal toxicity criteria, with grade ≥1 ARE defined as the primary endpoint. Sensitivity analyses were conducted using grade ≥2 and grade ≥3 ARE as more clinically relevant endpoints. mPNI was calculated from pre-radiotherapy total cholesterol level, albumin level and total lymphocyte count. During radiotherapy, 67 patients developed grade ≥1 ARE. Pre-radiotherapy mPNI was higher in the ARE group than in the non-ARE group [median, 88.27 (interquartile range, 81.26-97.02) vs. 76.41 (interquartile range, 70.22-80.38); P<0.001]. In the clinically adjusted logistic regression model, a higher mPNI remained significantly associated with grade ≥1 ARE [odds ratio (OR), 1.163; 95% confidence interval (CI), 1.072-1.261; P<0.001]. Sensitivity analyses likewise demonstrated significant associations between mPNI and grade ≥2 ARE (OR, 1.069; 95% CI, 1.023-1.117; P=0.003) and grade ≥3 ARE (OR, 1.071; 95% CI, 1.013-1.133; P=0.016). Receiver operating characteristic curve analysis showed good discriminatory performance for grade ≥1 ARE, with an area under the curve of 0.835 (95% CI, 0.732-0.917), an optimal cut-off value of 80.406, a sensitivity of 79.1% and a specificity of 76.0%. These findings suggest that pre-radiotherapy mPNI may serve as a practical laboratory-based indicator for identifying patients with cervical cancer at increased risk of developing ARE during radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.